Latest news

• Novartis: pipeline will generate 60 filings in three years

  Following after in MS is ofatumumab, a potential rival to Roche’s fast-growing CD20-targeting drug Ocrevus (ocrelizumab) that is already approved to treat blood cancers under the Arzerra (brand

• Roche’s new flu pill Xofluza approved in US

  This week saw the company unveil strong Q3 results, which managed to overcome the biosimilar onslaught, thanks to growth in new products such as multiple sclerosis drug Ocrevus.

• Spinraza lifts Biogen ahead of Alzheimer’s data

  from newer drugs such as Roche’s Ocrevus (ocrelizumab). ... MS drug sales came in at $2.3bn, with Tecfidera static at $1.09bn, and while Biogen gets a royalty stream from Ocrevus sales, that did little to counteract the impact

• Ocrevus surge keeps Roche smiling in Q3

  Sales of Roche’s new multiple sclerosis therapy Ocrevus more than tripled in the first nine months of 2018, helping to compensate for the loss of patent protection on its older ... Ocrevus (ocrelizumab) only made its debut in the US last year, but has

• Novartis files for approval of MS drug in EU, US

  That includes Roche‘s new therapy Ocrevus (ocrelizumab), a humanised monoclonal antibody designed to selectively target CD20-positive B cells, which has been approved in relapsing forms of MS and primary ... Ocrevus’ indications does however cover